Leerink Lifts PT on Ultragenyx Pharma (RARE) to $94 Amid Solid KRN23 Data in XLH

September 19, 2016 3:48 PM EDT
Get Alerts RARE Hot Sheet
Price: $70.74 -1.7%

Rating Summary:
    16 Buy, 1 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade RARE Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink boosts its price target on Ultragenyx Pharma (Nasdaq: RARE) from $85 to $94 after the company announced positive interim data from the ongoing pediatric Phase 2 study of KRN23 for the treatment of X-linked hypophosphatemia (XLH). The firm has Ultragenyx at Outperform.

The firm commented today, Ultragenyx presented updates to its KRN23 studies in Ph.2 pediatric X-linked hypophosphatemia (XLH) and Ph.2 tumor-induced osteomalacia (TIO) pts. at the American Society for Bone and Mineral Research (ASBMR) meeting. Notably, pediatric XLH pts. continued to demonstrate improvements in their bone health (as measured by radiography) while maintaining a favorable safety profile (including an asymptotic serum phosphorus level). In addition, data from TIO pts., albeit small (n=8), is suggestive of a possible label expansion beyond XLH.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Add Your Comment